Roche notches fresh win amid crowd of immunotherapy cocktails

ZURICH (Reuters) – Roche’s Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker’s immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *